Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 28, 2013; 19(8): 1318-1321
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1318
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1318
Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor
Guan-Min Lai, Cheng-Shyong Chang, Chien-Yu Tsai, Division of Hemato-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan
Sheng-Lei Yan, Division of Gastroenterology, Department of Internal Medicine, Chang-Bing, Show Chwan Memorial Hospital, Changhua 500, Taiwan
Author contributions: Lai GM and Yan SL contributed equally to this work; Lai GM and Yan SL contributed to the drafting the article; Chang CS, Yan SL and Tsai CY were responsible for the analysis and interpretation of the data; Chang CS was responsible for the critical revision and final approval of the article.
Correspondence to: Cheng-Shyong Chang, MD, Division of Hemato-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan. 15120@cch.org.tw
Telephone: +886-4-7238595 Fax: +886-4-7232946
Received: December 20, 2012
Revised: January 9, 2013
Accepted: January 23, 2013
Published online: February 28, 2013
Processing time: 71 Days and 13.7 Hours
Revised: January 9, 2013
Accepted: January 23, 2013
Published online: February 28, 2013
Processing time: 71 Days and 13.7 Hours
Abstract
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation.
Keywords: Hepatitis B virus; Chronic myeloid leukemia; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor